International Journal of Gynecology and Obstetrics logo Elsevier logo

Publisher: Elsevier

Related content
Volume 51, Number 1, October 1995

< previous issue | all issues | next issue >

The menopause revisited
pp. 1-13(13)
Author: Samsioe G.

Sociodemographic and clinical variables modifying the smoking-related risk of low birth weight
pp. 15-23(9)
Authors: Spinillo A.; Capuzzo E.; Iasci A.; Nicola S.; Piazzi G.; Baltaro F.

Placenta previa and previous cesarean section
pp. 25-31(7)
Authors: W. W.K.T.; W. C.L.

Prediction of early pregnancy outcomes
pp. 33-38(6)
Authors: Y. S.L.; C. H.L.

Dysplasia and HPV infection initially detected by DNA analysis in cytomorphologically normal cervical smears
pp. 43-48(6)
Authors: Saito J.; Sumiyoshi M.; Nakatani H.; Ikeda M.; Hoshiai H.; Noda K.

Body stalk anomaly: prenatal diagnosis
pp. 49-52(4)
Authors: Takeuchi K.; Fujita I.; Nakajima K.; Kitagaki S.; Koketsu I.

Sonographic appearance of uterine scar dehiscence
pp. 53-56(4)
Authors: Bromley B.; Pitcher B.L.; Klapholz H.; Lichter E.; Benacerraf B.R.

Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy
pp. 87-87(1)
Authors: Kuhn W.; Pache L.; Schmalfeldt B.; Dettmar P.; Schmitt M.; Janicke F.; Graeff H.

Ovarian cancer: Screening, treatment, and follow-up
pp. 87-88(2)
Authors: Seltzer V.; Batson J.L.; Drukker B.H.; Gillespie B.W.; Gossfeld L.M.; Grigsby P.W.; Harvey H.A.; Hendricks C.B.; Hummel S.; Makuch R.W.; Monaco G.P.; Parham G.P.; Sawyers C.L.; West R.J.

Salvage chemotherapy for epithelial ovarian carcinoma
pp. 88-88(1)
Authors: Christian M.C.; Trimble E.L.

Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol
pp. 88-89(2)
Authors: Carlson J.W.; Fowler J.M.; Saltzman A.K.; Carter J.R.; Chen M.D.; Mitchell S.K.; Dunn D.; Carson L.F.; Adcock L.L.; Twiggs L.B.

In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: Comparison of in vitro response and clinical outcome
pp. 89-89(1)
Authors: Federico M.; Alberts D.S.; Garcia D.J.; Emerson J.; Fanta P.; Liu R.; Salmon S.E.

Maturation of vaginal and endometrial epithelium in postmenopausal breast cancer patients receiving long-term tamoxifen
pp. 89-90(2)
Authors: Lahti E.; Vuopala S.; Kauppila A.; Blanco G.; Ruokonen A.; Laatikainen T.

Options for primary chemotherapy of epithelial ovarian cancer: Taxanes
pp. 90-90(1)
Authors: Trimble E.L.; Arbuck S.G.; McGuire W.P.

Chemotherapy in advanced ovarian carcinoma: Current standards of care based on randomized trials
pp. 90-91(2)
Authors: Thigpen T.; Vance R.; Puneky L.; Khansur T.

Options for primary chemotherapy in advanced ovarian cancer: The European perspective
pp. 91-91(1)
Authors: Colombo N.; Maggioni A.; Vignali M.; Parma G.; Mangioni C.

Hard choices: The gynecologic cancer patient's end-of-life preferences
pp. 91-91(1)
Authors: Brown D.; Roberts J.A.; Elkins T.E.; Larson D.; Hopkins M.

Mother-to-infant transmission of hepatitis C virus
pp. 91-91(1)
Authors: Zanetti A.R.; Tanzi E.; Paccagnini S.; Principi N.; Pizzocolo G.; Caccamo M.L.; D'Amico E.; Cambie G.; Vecchi L.; Bresciani S.; Martin M.G.; Padula D.; Rodella A.; Bulgarelli I.; Chiodo F.; Magliano E.; Miotto G.; Muggiasca M.L.; Pilloton E.

Metabolic approaches to the subclassification of polycystic ovary syndrome
pp. 92-93(2)
Authors: Norman R.J.; Masters S.C.; Hague W.; Beng C.; Pannall P.; Wang J.X.

Prevalence of hepatitis B, hepatitis C, and human immunodeficiency virus infection among women attending prenatal clinics in San Juan, Puerto Rico, from 1989-1990
pp. 92-92(1)
Authors: Deseda C.C.; Sweeney P.A.; Woodruff B.A.; Lindegren M.L.; Shapiro C.N.; Onorato I.M.

Diagnosis of Chlamydia trachomatis genitourinary infection in women by ligase chain reaction assay of urine
pp. 92-92(1)
Authors: Lee H.H.; Chernesky M.A.; Schachter J.; Burczak J.D.; Andrews W.W.; Muldoon S.; Leckie G.; Stamm W.E.

Improving office-based physicians' prevention practices for sexually transmitted diseases
pp. 92-92(1)
Authors: Rabin D.L.; Boekeloo B.O.; Marx E.S.; Bowman M.A.; Russell N.K.; Gonzalez W.A.

Neurohormonal and hemodynamic changes in severe cases of the ovarian hyperstimulation syndrome
pp. 93-93(1)
Authors: Balasch J.; Arroyo V.; Fabregues F.; Salo J.; Jimenez W.; Pare J.C.; Vanrell J.A.

The morning-after pill -- How long after?
pp. 93-93(1)
Authors: Grou F.; Rodrigues I.

Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy
pp. 93-94(2)
Authors: Suhonen S.P.; Holmstrom T.; Allonen H.O.; Lahteenmaki P.

Hormone replacement therapy and endometrial cancer risk: A meta-analysis
pp. 94-94(1)
Authors: Grady D.; Gebretsadik T.; Kerlikowske K.; Ernster V.; Petitti D.

Decline in semen quality among fertile men in Paris during the past 20 years
pp. 94-95(2)
Authors: Auger J.; Kunstmann J.M.; Czyglik F.; Jouannet P.

Increased capillary permeability induced by human follicular fluid: A hypothesis for an ovarian origin of the hyperstimulation syndrome
pp. 96-96(1)
Authors: Goldsman M.P.; Pedram A.; Dominguez C.E.; Ciuffardi I.; Levin E.; Asch R.H.

Urinary complaints after modified Burch urethropexy: An analysis
pp. 97-97(1)
Authors: Byck D.B.; Varner R.E.; Clough C.

< previous issue | all issues | next issue >

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page